GlassScriptPhysician profile
Kelly M James
NPI 1366428302
$105,707.09
in general payments reported to CMS, 2019-2025
28 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $6,042 · 2021: $461 · 2022: $13K · 2023: $17K · 2024: $34K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Consulting Fee: $23K · Travel and Lodging: $9,081 · Food and Beverage: $3,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,771.88 |
| Consulting Fee | $22,690.00 |
| Travel and Lodging | $9,080.61 |
| Food and Beverage | $3,924.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $96,267.62 | 2019-2025 | Pico, Oasis, Grafix |
| Aroa Biosurgery Incorporated | $5,123.33 | 2019-2024 | |
| Senseonics, Incorporated | $1,200.00 | 2025 | Eversense |
| Organogenesis INC. | $988.09 | 2019-2025 | Puraply Wound Matrix, Apligraf, Affinity |
| Integra Lifesciences Corporation | $531.14 | 2020-2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Acera Surgical, INC. | $344.59 | 2019-2025 | Restrata Wound Matrix |
| Ascensia Diabetes Care US INC. | $240.00 | 2024 | |
| Convatec INC. | $197.82 | 2024 | |
| Kerecis Limited | $158.24 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Wright Medical Technology, INC. | $114.25 | 2019 | |
| Polynovo North America LLC | $85.37 | 2022-2024 | Novosorb Btm |
| Z-Medica, LLC | $63.12 | 2019 | |
| Davol INC. | $41.26 | 2020-2022 | |
| Medline Industries LP | $35.67 | 2019 | |
| Melinta Therapeutics, LLC | $35.64 | 2024-2025 | Kimyrsa, Orbactiv |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $31.30 | 2025 | |
| Ethicon US, LLC | $30.39 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $30.22 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $28.38 | 2024 | |
| Bioventus LLC | $25.96 | 2022 | |
| Abbvie INC. | $24.25 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $16.98 | 2021 | |
| 3m Company | $16.53 | 2019 | |
| Lifenet Health | $16.48 | 2024 | Theragenesis Wound Matrix |
| Tei Medical INC. | $15.81 | 2019 | |
| Hologic Sales and Service, LLC | $15.53 | 2023 | Coolseal Generator |
| Acell, INC. | $15.37 | 2020 | |
| Endo Pharmaceuticals INC. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.